Carbidopa and levodopa for Parkinson’s disease treatment

Carbidopa and levodopa tablets combine two drugs used to treat Parkinson’s disease and related parkinsonism conditions. This oral medication helps relieve symptoms like tremors, stiffness, and slow movements by increasing dopamine levels in the brain. Carbidopa enhances levodopa’s effectiveness and reduces its side effects by preventing its conversion outside the brain.

This medication is prescribed for adults to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism resulting from carbon monoxide or manganese poisoning. It is not recommended for pediatric patients (under 18 years).

Carbidopa; Levodopa

Parkinson’s disease symptoms stem from dopamine deficiency in the brain. Dopamine itself cannot cross the blood-brain barrier, but levodopa, its precursor, can. After crossing into the brain, levodopa converts to dopamine, helping restore brain dopamine levels and improve movement control.

Carbidopa inhibits the peripheral breakdown of levodopa, increasing the amount of levodopa reaching the brain and reducing side effects like nausea caused by dopamine formed outside the brain. Carbidopa does not cross into the brain and does not affect dopamine metabolism centrally.

The tablets come in three strengths combining fixed amounts of carbidopa and levodopa: 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg. Dosage and frequency are individualized based on patient response and tolerance. Prior to starting carbidopa and levodopa therapy, levodopa alone should be discontinued for at least 12 hours.

It is important to take the medication at regular intervals as prescribed and avoid changing the regimen or adding other Parkinson’s medications without consulting a healthcare provider.

• Hypersensitivity to carbidopa, levodopa, or any tablet component.
• Concurrent use of nonselective MAO inhibitors (not discontinued at least 2 weeks prior).
• Narrow-angle glaucoma.

• Drug interactions: Avoid use with nonselective MAO inhibitors (stop at least 2 weeks before starting this medication). Selective MAO-B inhibitors (e.g., selegiline) can be used with caution.
• Central nervous system effects: Carbidopa and levodopa can cause dyskinesias and hallucinations, sometimes requiring dose adjustments.
• Sudden sleep episodes: Patients may suddenly fall asleep during daily activities without warning. Patients should be cautioned about driving or operating machinery, especially if somnolence occurs.
• Neuroleptic malignant syndrome (NMS): Abrupt withdrawal or dose reduction can cause NMS, a life-threatening condition characterized by fever, muscle rigidity, and altered mental status.
• Vitamin B6 deficiency: Use may lead to vitamin B6 deficiency and related seizures; monitoring and supplementation may be needed.
• Cardiovascular precautions: Use cautiously in patients with severe cardiac or pulmonary disease and monitor during initial dose adjustment.
• Other serious conditions: Monitor for depression with suicidal tendencies, gastrointestinal bleeding, and glaucoma exacerbation.

Common adverse effects include involuntary movements (dyskinesias) and nausea. Other reported side effects involve cardiovascular issues (irregular heartbeats, hypotension), gastrointestinal symptoms (vomiting, constipation, dark saliva), hematologic abnormalities (anemia), psychiatric effects (hallucinations, confusion), and others such as asthenia and chest pain.

• Nonselective MAO inhibitors: contraindicated, require discontinuation at least 2 weeks prior.
• Selective MAO-B inhibitors (selegiline): may cause severe orthostatic hypotension.
• Antihypertensive agents: may cause symptomatic hypotension; dose adjustment might be needed.
• Tricyclic antidepressants, dopamine D2 antagonists (e.g., phenothiazines, risperidone), isoniazid, phenytoin, papaverine: may reduce levodopa effectiveness or increase adverse effects.
• Dopamine-depleting agents (reserpine, tetrabenazine): use not recommended with this medication.
• Iron salts or multivitamins containing iron: may reduce levodopa/carbidopa bioavailability.
• Metoclopramide: may increase levodopa bioavailability but impair disease control due to dopamine antagonism.

Pregnancy: Animal studies showed malformations and reduced live births at high doses. There are no adequate human studies. Levodopa crosses the placenta; carbidopa levels in fetal tissue are minimal. Use only if benefits outweigh risks.

Lactation: Levodopa is present in human milk; caution advised during breastfeeding.

No specific storage instructions provided in the label.